12月25日，孚诺医药旗下新药孚立美®氟轻松氢醌维A酸乳膏在京东健康开启独家预约，为中重度黄褐 斑患者带来科学祛斑新方案。用户通过京东APP搜索"孚立美"即可预约。 目前，孚立美®已在京东健康正式开启独家预约，用户可通过京东APP搜索"孚立美"，在线咨询专业医 师后完成处方开具与购买，足不出户即可获得规范治疗方案。针对首次预约用户，还可享受医师一对一 用药指导、全程疗效跟踪等专属服务，让科学祛斑更省心、更安心。 作为国内首款获批的Kligman配方制剂，孚立美®配方包含0.01%氟轻松、4%氢醌、0.05%维A酸三种精 准配比的活性成分，三者协同发力：氢醌强效阻断黑素生成，维A酸加速色素脱落并促进药物渗透，氟 轻松则减轻皮肤刺激、稳定皮肤状态。 临床数据显示，使用孚立美®治疗4周即可看到明显淡斑效果，8周为一个标准疗程，整体有效率高达 68.57%，部分患者治疗12个月后完全或接近清除率可达94%。更值得关注的是，其疗效与原研产品等 效，且不良反应发生率更低，安全性更优。 针对黄褐斑易复发的痛点，孚立美®在8周标准治疗后可采用梯度维持方案：第9-12周隔天一次，第13- 16周每周两次，第17-20周每周一次 ...

Core Viewpoint - JD Health and H&H Group have signed a strategic cooperation agreement to deepen their collaboration over the next three years, aiming for a combined business target of 10 billion [2][7]. Group 1: Partnership Development - The partnership marks an upgrade to a comprehensive and in-depth strategic relationship after ten years of close cooperation [2][7]. - Since their first collaboration in 2015, JD Health and H&H Group have worked together for a decade [4][9]. Group 2: Product and Marketing Initiatives - In 2025, H&H Group's key products, including Swisse high-purity fish oil and Biostime super probiotics, will be launched exclusively on JD Health [4][9]. - The two companies have collaborated on significant marketing initiatives, including sponsoring the popular variety show "Flowers and Youth: Together Season" and creating the "Ace Super Product Day" marketing IP [4][9]. Group 3: Future Collaboration Focus - In 2026, the partnership will focus on four key areas: products, marketing, user experience, and mechanisms, with increased resource investment to achieve new growth breakthroughs [4][9]. - Future collaboration will enhance supply chain efficiency, user health management, and data-driven innovation, leveraging JD Health's integrated sales and supply chain capabilities [5][9]. Group 4: Strategic Goals and Vision - JD Health aims to provide more precise and personalized health solutions for families, supporting the long-term sustainable development of H&H Group's diverse nutrition product lines [5][9]. - H&H Group's CEO expressed that JD Health is one of their most important partners in the Chinese market, emphasizing the integration of global quality nutrition resources with JD Health's digital technology and user insights [5][9]. - JD Health's CEO stated the intention to deepen strategic collaboration across all channels and links, aiming for reliable and scientifically professional nutrition health services to reach more families [5][9].

Core Insights - Dain Pharmaceutical has launched the melatonin granules, Manlejing®, for the treatment of sleep disorders in children with neurodevelopmental disorders, marking it as the only approved melatonin medication in China for this purpose [1][2] - The introduction of Manlejing® addresses a significant health challenge, as nearly half of children with conditions like autism spectrum disorder and attention deficit hyperactivity disorder experience sleep issues that affect their overall development [1] Group 1 - Manlejing® is designed in a granule form with a sweet taste, making it easier for children to consume [1] - Clinical studies indicate that after two weeks of using Manlejing®, children's sleep onset latency is reduced by over 36 minutes, significantly alleviating difficulties in falling asleep [2] - Continuous use of Manlejing® leads to improvements in both nighttime sleep and daytime behavior, helping to reduce issues such as hyperactivity, irritability, and inappropriate language [2] Group 2 - The International Pediatric Sleep Association (IPSA) and the American Academy of Neurology (AAN) recommend that children use pharmaceutical-grade melatonin, reinforcing the credibility of Manlejing® [2] - JD Health plans to leverage its robust pharmaceutical health service ecosystem to collaborate with Dain Pharmaceutical and other renowned companies to introduce cutting-edge therapeutic drugs, aiming to provide comprehensive digital health management solutions for affected children [2]

Core Insights - The integration of digital transformation and the "Healthy China" strategy has elevated corporate health management from a traditional welfare option to a critical variable for organizational resilience and growth certainty [1] - JD Health is emerging as a core driver in the rapidly growing market, leveraging its unique advantages such as a vast customer base and comprehensive health service capabilities [1][3] - The establishment of the "2026 Billion Brand Alliance" aims to enhance collaboration and accelerate market penetration for partner brands in the corporate health sector [6] Market Dynamics - The corporate health consumption market is experiencing explosive growth driven by policy support, corporate demands, and heightened employee health awareness [1] - JD Health's enterprise business has seen significant performance, with over 800 partner brands and a notable number achieving sales in the millions [3] Strategic Development - JD Health has outlined three core development directions for 2026: solidifying product and supply chain foundations, scaling centralized procurement models, and strategically investing in corporate medical funds [1][6] - The company is transitioning from a "behind-the-scenes supplier" to a "direct service provider" in the medical fund sector, which has shown nearly 100% growth in 2025 [8][9] Service Innovation - JD Health is focusing on creating a comprehensive health service ecosystem that integrates various health management scenarios, including emergency response and chronic disease management [4][5] - The company is enhancing its digital capabilities through AI tools to provide precise service matching and improve the overall employee health management experience [4][6] Competitive Advantages - JD Health's competitive edge lies in its robust supply chain, strong service capabilities, and deep integration of digital tools, which collectively enhance its market position [3][4] - The company is committed to transforming employee health management into a core driver of organizational productivity and high-quality development [2][10]

12月18日，京东健康企业业务商家大会暨2026年亿元品牌联盟成立仪式在京举行。大会围绕"以力聚新，同心共健"主题， 与参会嘉宾共同就企业健康消费市场的发展机遇、数字化升级路径、阳光采购生态共建等方向，深入探讨如何通过供应链合 力，来为企业客户带来更优质、便捷、全面的健康产品与服务体验。 京东集团SEC委员、京东健康CEO曹冬在致辞中指出，"员工健康即是企业生产力"已成为广泛共识，企业健康管理正从福 利选项演进为组织发展的关键基石。京东健康依托京东集团超千亿的企业市场规模和百万级客户基础，以及自身具有的"超级 医药供应链"能力，致力于成为企业健康消费领域最值得信赖的首选合作企业。 2025年，京东健康表现强劲，营收与盈利实现双增长，合作商家数量已突破15万家。京东健康企业业务合作品牌超过800 个，其中在企业端市场，销售额千万级以上合作品牌达20余个，百万级以上合作品牌超200个，呈现出高质量增长态势。 京东集团副总裁、政企业务总裁李永明在分享中指出，京东深耕政企采购行业超十年，服务超800万家政企客户，其中涵 盖3万多家大型企业，为品牌商构筑广阔增长空间。今年以来，营养、保健、滋补、医疗器械等健康品类在政企 ...

Group 1 - The core theme of the event was "Gathering Strength for New Beginnings, United for Health," focusing on the digital upgrade and ecological co-construction of the corporate health consumption market [2] - JD Health's CEO highlighted that "employee health is corporate productivity," indicating a shift in corporate health management from a welfare option to a key support for organizational development [2] - By 2025, JD Health's corporate business is expected to achieve high-quality growth with over 800 cooperative brands, including more than 20 brands with sales exceeding 10 million and over 200 brands with sales exceeding 1 million [2] Group 2 - JD Group has been deeply involved in the government and enterprise procurement sector for over ten years, serving more than 8 million government and enterprise clients, including over 30,000 large enterprises [2] - In 2023, health product categories such as nutrition, health supplements, and medical devices have seen explosive growth in government and enterprise procurement, with over 100 subcategories experiencing year-on-year growth exceeding 100% [2] - JD Health's corporate business has outlined three development directions for 2026: "Foundation Action" focusing on supply chain and product capability construction, "Wildfire Plan" aimed at large-scale replication of centralized procurement models, and "Doubling Battle" concentrating on expanding the corporate medical insurance sector [2] Group 3 - The establishment of the 2026 JD Health Corporate Business Billion Brand Alliance aims to consolidate leading brand power and deepen ecological cooperation [3] - Representatives from five companies, including Haishi Hainuo, Mindray Medical, Yiyue E-commerce, Tongrentang Health, and Xiangyu Medical, participated in the launch ceremony [3]

Core Insights - JD Health has established the "2026 Billion Brand Alliance" with five brands to accelerate market expansion in the government and enterprise sectors [1][3] - The CEO of JD Health emphasized that employee health is now recognized as a key driver of organizational productivity, shifting health management from a welfare option to a foundational element of development [1][3] - JD Health aims to become the most trusted partner in the corporate health consumption sector, leveraging JD Group's extensive market scale and supply chain capabilities [1][3] Company Performance - By 2025, JD Health's partner merchants exceeded 150,000, with over 800 brands collaborating in the enterprise market [1][3] - More than 20 brands have achieved sales exceeding 10 million, while over 200 brands have surpassed 1 million in sales within the enterprise sector [1][3] - JD Group has served over 8 million government and enterprise clients, including more than 30,000 large enterprises, with significant growth in health-related product categories [1][3] Strategic Directions - JD Health has outlined three core development strategies for 2026: "Foundation Action," "Prairie Fire Plan," and "Doubling Battle" [4][5] - "Foundation Action" focuses on strengthening product and supply chain foundations, enhancing B2B supply chain collaboration, and improving customer satisfaction and repurchase rates [5] - "Prairie Fire Plan" aims to innovate centralized procurement models and scale them, addressing various corporate health needs [5] - "Doubling Battle" targets the rapidly growing corporate medical fund sector, offering integrated health benefits and claims solutions to create competitive advantages [5]

Core Insights - The 2025 JD Health Pediatric Ecosystem Conference was held in Beijing, focusing on children's health and the establishment of a Pediatric Ecosystem Partner Alliance with various pharmaceutical companies [1][2] - JD Health is addressing challenges in children's medication through a comprehensive "three-full model" that includes categories, brands, and products, aiming to enhance the efficiency and quality of drug circulation [2] Group 1: Pediatric Ecosystem Development - JD Health has partnered with over 20 pharmaceutical companies to form the Pediatric Ecosystem Partner Alliance, which aims to improve the supply of pediatric medications and enhance healthcare resources for children [2] - The conference featured discussions on children's health product development, brand marketing, and the integration of e-commerce within the healthcare ecosystem [1][2] Group 2: Product and Brand Strategy - JD Health covers nine core categories of pediatric medications, including treatments for common ailments and neurological conditions, and provides scientific medication knowledge through "200 Questions on Science" [2] - The company collaborates with over 200 industrial brands to ensure high-quality and cost-effective medication for children, offering over 460 pediatric products [2] Group 3: Special Medical Foods - JD Health is the largest online retail channel for special medical foods in China, with 286 approved products available for home use, including 45 specialized infant formula products for children under one year old [2] - The company aims to provide reliable nutritional support for children with allergies and those needing nutritional supplements through its specialized medical food offerings [2]

Core Insights - The 2025 JD Health Pediatric Ecosystem Conference was held in Beijing, focusing on the theme "Child's Heart, Medicine Health, Science Popularization Accompanies Growth" [1] - JD Health established a Pediatric Ecosystem Partner Alliance with various health brands to ensure children have access to necessary medications [8] Group 1: Conference Highlights - Experts from top medical institutions and pharmaceutical companies shared insights on topics such as pediatric respiratory diseases, epilepsy treatment, mental health, and infant growth [3] - A professor from Shenzhen Children's Hospital discussed the impact of climate change on children's respiratory health, emphasizing the need for pollen monitoring and health education to prevent adverse effects [3] Group 2: Pediatric Health Challenges - A pediatric neurology expert highlighted that approximately 10 million epilepsy patients exist in China, with 40% being children, and identified challenges such as insufficient early diagnosis and lack of innovative treatment accessibility [5] - Common mental health issues in children, such as ADHD and anxiety disorders, were discussed, with an emphasis on the importance of balanced development rather than academic pressure [5] Group 3: Pharmaceutical Industry Insights - Pharmaceutical representatives discussed the development of children's health products, emphasizing the need for a robust research and development system based on clinical and user needs [5] - A company representative mentioned strategies to enhance brand credibility and market reach through expert knowledge and innovative marketing approaches [6] Group 4: JD Health's Initiatives - JD Health is addressing challenges in children's medication by implementing a comprehensive model that includes product categories, brand partnerships, and a wide range of pediatric products [7] - The company has established deep collaborations with over 200 industrial brands to improve the efficiency and quality of drug distribution [7] - JD Health is recognized as the most comprehensive online retail channel for special medical foods in China, offering a variety of products suitable for children [7]

Core Insights - The third annual conference of the China Anti-Aging Promotion Association's Functional Medicine Professional Committee was held in Shanghai, gathering nearly a thousand experts and industry representatives to discuss advancements in functional medicine for chronic disease management and health promotion [1][2]. Company Overview - JD Health's high-end health management channel is based on internationally certified functional medicine and lifestyle medicine principles, aiming to provide systematic health services that address the root causes of health issues rather than just symptoms [1][2]. - The channel features certified functional medicine and lifestyle medicine experts with international perspectives and rich clinical experience, offering comprehensive health consultations and personalized intervention plans [2]. Service Offerings - The health management process includes health information collection, one-on-one expert consultations, personalized testing and intervention plan development, and regular follow-ups, creating a complete health management loop [2]. - The channel specializes in addressing metabolic and organic issues such as diabetes, thyroid nodules, and breast nodules, as well as complex health conditions like ovarian insufficiency, chronic fatigue, anxiety, depression, and gastrointestinal dysfunction [2]. Industry Trends - As public health awareness increases and health needs become more refined, functional medicine is transitioning from theory to clinical application, showcasing broad application prospects [3]. - JD Health plans to leverage its platform advantages and professional team to promote the standardized development and innovative practices of functional medicine in China, helping users achieve proactive and root-cause health management [3].